

Office Action Summary	Application No.	Applicant(s)	
	09/297,090	GORANSSON ET AL.	
	Examiner Shengjun Wang	Art Unit 1617	
-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --			
Period for Reply			
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.			
<ul style="list-style-type: none"> - Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). 			
Status			
1) <input type="checkbox"/> Responsive to communication(s) filed on _____.			
2a) <input type="checkbox"/> This action is FINAL. 2b) <input checked="" type="checkbox"/> This action is non-final.			
3) <input type="checkbox"/> Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.			
Disposition of Claims			
4) <input checked="" type="checkbox"/> Claim(s) <u>1-9</u> is/are pending in the application.			
4a) Of the above claim(s) _____ is/are withdrawn from consideration.			
5) <input type="checkbox"/> Claim(s) _____ is/are allowed.			
6) <input checked="" type="checkbox"/> Claim(s) <u>1-9</u> is/are rejected.			
7) <input type="checkbox"/> Claim(s) _____ is/are objected to.			
8) <input type="checkbox"/> Claims _____ are subject to restriction and/or election requirement.			
Application Papers			
9) <input type="checkbox"/> The specification is objected to by the Examiner.			
10) <input type="checkbox"/> The drawing(s) filed on _____ is/are objected to by the Examiner.			
11) <input type="checkbox"/> The proposed drawing correction filed on _____ is: a) <input type="checkbox"/> approved b) <input type="checkbox"/> disapproved.			
12) <input type="checkbox"/> The oath or declaration is objected to by the Examiner.			
Priority under 35 U.S.C. § 119			
13) <input checked="" type="checkbox"/> Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).			
a) <input checked="" type="checkbox"/> All b) <input type="checkbox"/> Some * c) <input type="checkbox"/> None of the CERTIFIED copies of the priority documents have been:			
1. <input checked="" type="checkbox"/> received.			
2. <input type="checkbox"/> received in Application No. (Series Code / Serial Number) _____.			
3. <input type="checkbox"/> received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).			
* See the attached detailed Office action for a list of the certified copies not received.			
14) <input type="checkbox"/> Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).			
Attachment(s)			
15) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)			
16) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)			
17) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____			
18) <input type="checkbox"/> Interview Summary (PTO-413) Paper No(s) _____			
19) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)			
20) <input type="checkbox"/> Other: _____			



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
09/297,090	07/09/99	GORANSSON	L REF/970230/L
		HM12/0912	EXAMINER
BACON & THOMAS 625 SLATERS LANE 4TH FLOOR ALEXANDRIA VA 22314-1176			WANG, S
		ART UNIT	PAPER NUMBER
		1617	8
DATE MAILED: 09/12/00			

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

DETAILED ACTION

Claim Objection

1. Claims 1 and 7 are objected to because of the following informalities: The employment of parenthetical expression, (ASP), in claims is considered informal. Appropriate correction is required.

Claim Rejections 35 U.S.C. - 112

2. The following is a quotation of the second paragraph of 35 U.S.C. 112:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
3. Claims 1-6 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
4. Claims 1-6 provides for the use of products having enzymatic activity, but, since the claim does not set forth any steps involved in the method/process, it is unclear what method/process applicant is intending to encompass. A claim is indefinite where it merely recites a use without any active, positive steps delimiting how this use is actually practiced.

Claims 1-6 are rejected under 35 U.S.C. 101 because the claimed recitation of a use, without setting forth any steps involved in the process, results in an improper definition of a process, i.e., results in a claim which is not a proper process claim under 35 U.S.C. 101. See for example *Ex parte Dunki*, 153 USPQ 678 (Bd. App. 1967) and *Clinical Products, Ltd. v. Brenner*, 255 F. Supp. 131, 149 USPQ 475 (D.D.C. 1966).

In order to expedite the prosecution, claims 1-6 have been examined on the merits as method of making claims.

Claim Rejections 35 U.S.C. - 103

5. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

6. Claims 1-9 are rejected under 35 U.S.C. 103(a) as being unpatentable over Bolles et al.

(US 4,834,989) and Camburn (US 5,552,175) in view of Witt et al. (US 4,241,183).

7. Bolles et al. teach a flaked cereal and the method of making the same. The method

comprising employing products having enzymatic activity, such as malted wheat, malted barley or malted sorghum. See, the abstract, column 3, lines 47-53, column 24-39. Camburn further teach a powdered foodstuff prepared with malted cereals. See, the examples in columns 6-9.

8. The primary references do not teach expressly to make a product that when consumed, induces antisecretory proteins (ASP) regulating the flux of fluid and electrolytes in the intestine so that 1 ml of blood will contain at least 0.5 units of ASP.

9. However, the instant application does not specifically define the amounts of malted

cereal in the foodstuff. See, page, 3, lines 29-33 in the specification. Witt et al. teach that it is well known that malted cereal contain enzyme and are widely used in food products. See, column 1, lines 5-10. It appears that there is not particular limit in term of amounts for malted cereal to be employed in food products.

10. Therefore, it would have been *prima facie* obvious to a person of ordinary skill in the art,

at the time the claimed the invention was made, to employ certain amounts of malted cereal in the product of Bolles et al. where in the amount of malted cereal is proper to induce antisecretory

proteins (ASP) regulating the flux of fluid and electrolytes in the intestine so that 1 ml of blood will contain at least 0.5 units of ASP because there is no particular limitation in term of amount for employment of malted cereals in food product and employment of any amount of malted cereal in food products is seen to be fairly suggested by the prior art. Further, the intended use of a product does not render patentable weight on a claim drawn to the product or the method of making the product.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Shengjun Wang, Ph.D. whose telephone number is (703) 308-4554. The examiner can normally be reached on Monday-Friday from 8:30 to 5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Minna Moezie, J.D., can be reached on (703) 308-4612. The fax phone number for the organization where this application or proceeding is assigned is (703) 308-4556.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-1235.

Shengjun Wang

AU 1617

September 2, 2000


MINNA MOEZIE, J.D.
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600